It will be interesting to watch deferred revenue on balance sheet as a proportion of revenue, over upcoming announcements.
That may paint a reasonable picture as to future, near-term revenue growth. My understanding is that only license-based income streams are paid upfront, and therefore only they are recorded as deferred revenue.
If my understanding is correct, the $5.2m in deferred revenue (a $2.65m increase on last year's annual report) indicates there's actually a lot more going on than what the business is explicitly saying, and even though it's not necessarily ARR, some of these license-based contracts may continue to roll-over (given low customer churn) and in effect actually become more akin to ARR.
Crucially, if my understanding is correct - that this is purely license-based - then the quality of revenues is materially improving. Total revenue for last FY was $6.4m (from which license revs was $3.2m).
Assuming my understanding is correct, the business will for FY24 receive 81.25% of FY23's total revenue, via license-based revenues only.
How the revenue distribution looks going forward will be important, but this is painting a picture consistent with Daniel Lai's comments in various presentations about the existing service-based contracts likely to cause a significant pull-through, or slingshot of license-based revenue.
The firm has been relatively silent - much to my (and no doubt many shareholders') chagrin - but the numbers are certainly providing support for the verbal context Daniel and Kurt have provided in investor presentations.
- Forums
- ASX - By Stock
- AR9
- Ann: Appendix 4E & 2023 Annual Report
Ann: Appendix 4E & 2023 Annual Report, page-88
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AR9 (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.2¢ |
Change
0.003(4.35%) |
Mkt cap ! $20.35M |
Open | High | Low | Value | Volume |
6.9¢ | 7.2¢ | 6.9¢ | $12.96K | 181.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1082 | 7.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.4¢ | 81155 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5656 | 0.072 |
1 | 128150 | 0.069 |
3 | 320506 | 0.068 |
1 | 4477 | 0.067 |
3 | 175538 | 0.066 |
Price($) | Vol. | No. |
---|---|---|
0.074 | 81155 | 2 |
0.075 | 10000 | 1 |
0.077 | 180000 | 1 |
0.078 | 10000 | 1 |
0.079 | 49500 | 1 |
Last trade - 15.12pm 18/11/2024 (20 minute delay) ? |
Featured News
AR9 (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
SPONSORED BY The Market Online